Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars

17. September 2021 aktualisiert von: Castle Creek Biosciences, LLC.

A Phase II, Double-Blind, Randomized, Placebo-Controlled Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars

This Phase II, double-blind, randomized, placebo-controlled pilot study is designed to determine whether injection of autologous fibroblasts can increase the mobility (decrease the restriction) of burn scars. The study will assess the effects of azficel-T (autologous fibroblasts) in subjects who have a unilateral burn scar that is no deeper than the fascia (i.e., underlying structures including ligament, tendon, muscle, and bone must not contribute to the restriction) and that is either:

  1. An axillary scar causing 20-60% restriction of shoulder adduction
  2. An anterior elbow scar causing 20-60% restriction of elbow extension
  3. A dorsal or palmar lesion of a single finger causing 20-60% restriction of flexion or extension

Subjects will each receive 2 injections of azficel-T or placebo administered 14 days (± 7 days) apart (depending on cell availability) and will be followed for efficacy (including range of motion measurements, scar pain and ability to perform activities) to Visit 7 and for safety to Visit 9 at 1 year.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Tatsächlich)

5

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • California
      • Sacramento, California, Vereinigte Staaten, 95817
        • Univ of California David Medical Center
      • San Diego, California, Vereinigte Staaten, 92103
        • Univ of California San Diego
    • Florida
      • Miami, Florida, Vereinigte Staaten, 33136
        • Division of Burns and Trauma, Jackson Memorial Hospital
    • Illinois
      • Maywood, Illinois, Vereinigte Staaten, 60153
        • Loyola University Medical Center
    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46202
        • Richard M. Fairbanks Burn Center
    • New York
      • Garden City, New York, Vereinigte Staaten, 11530
        • Long Island Plastic Surgical Group
    • Pennsylvania
      • Allentown, Pennsylvania, Vereinigte Staaten, 18103
        • Lehigh Valley Health Network
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
        • Center for Innovation in Restorative Medicine
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98104
        • Univ of Washington, Harborview Medical Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Subject is at least 18 years of age
  2. Subject has a unilateral burn scar of a jointed area (i.e., finger, elbow, shoulder) that is no deeper than the fascia (i.e., underlying structures including ligament, tendon, muscle, and bone must not contribute to the restriction) and that is either:

    1. An axillary scar causing 20-60% restriction of shoulder abduction
    2. An anterior elbow scar causing 20-60% restriction of elbow extension
    3. A dorsal or palmar lesion of a single finger causing 20-60% restriction of flexion or extension
  3. Subject's burn scar to be treated is <100 sq cm in size
  4. Injury occurred ≤ 36 months prior to screening
  5. By the Investigator's assessment, physical therapy will not provide significant continuous improvement to the range of motion of the subject's joint
  6. Subject agrees to maintain any current physical therapy regimen for the duration of the study
  7. Subject must be able to provide written informed consent and comply with the study requirements
  8. Females of childbearing potential must have a negative urine pregnancy test at the screening visit and prior to the first treatment, and must agree to use a reliable means of birth control for the duration of the study
  9. Subject has healthy, non-scarred post auricular skin area suitable for biopsy
  10. Subject must have a normal complete blood count (CBC) and chemistry panel within 90 days prior to enrollment

Exclusion Criteria:

  1. Restrictive burn scars that are primarily classified as keloid scars
  2. Subjects for whom a post auricular biopsy cannot be collected for azficel-T production
  3. Sunburn or sun damage in the area that will be used for biopsy
  4. Plans to initiate any other new scar therapy during the study period
  5. Treatment with an investigational product or procedure within 30 days prior to study enrollment or plans to participate in another clinical trial during the course of this study
  6. History of active autoimmune disease or organ transplantation
  7. Diagnosis of cancer, including basal cell carcinoma, unless successfully treated or in remission for a minimum of 6 months
  8. Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia, osteogenesis imperfecta, epidermolysis bullosa, ataxia-telangiectasia, Ehlers Danlos syndrome, etc.
  9. Active systemic infection
  10. Requires chronic antibiotic or steroidal therapy
  11. Any conditions that are considered by the Investigator to be contraindications to biopsy or injection
  12. Pregnant or lactating women, or women trying to become pregnant during the study
  13. Subject has any disorder that may prevent compliance, such as history of chronic alcohol or drug abuse, significant mental or nervous disorder or other illness that would, in the Investigator's opinion, interfere with the study
  14. Presence of other disease or condition that would result in impairment of the range of motion of the extremity, e.g., rheumatoid arthritis or stroke

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Autologous fibroblasts
Autologous fibroblasts grown in culture from skin biopsy taken from patient. The cells will be injected into the scars to be treated.
Andere Namen:
  • Azficel-T
Placebo-Komparator: Sterile saline
Sterile saline will be injected into the scar to be evaluated.
Andere Namen:
  • Azficel-T

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage Change From Baseline (CFB) of Range of Motion (ROM) of the Affected Joint
Zeitfenster: Baseline and post-treatment (visit occurred between 194 - 208 days from baseline)
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
Baseline and post-treatment (visit occurred between 194 - 208 days from baseline)
Percentage CFB of ROM of the Affected Joint
Zeitfenster: Baseline and post-treatment (visit occurred between 23 - 37 days from baseline)
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
Baseline and post-treatment (visit occurred between 23 - 37 days from baseline)
Percentage CFB of ROM of the Affected Joint
Zeitfenster: Baseline and post-treatment (visit occurred between 53 - 67 days from baseline)
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
Baseline and post-treatment (visit occurred between 53 - 67 days from baseline)
Percentage CFB of ROM of the Affected Joint
Zeitfenster: Baseline and post-treatment (visit occurred between 93 - 97 days from baseline)
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
Baseline and post-treatment (visit occurred between 93 - 97 days from baseline)
Percentage CFB of ROM of the Affected Joint
Zeitfenster: Baseline and post-treatment (visit occurred between 113 - 127 days from baseline)
Percentage CFB was calculated by subtracting the baseline ROM measurement from the post-treatment ROM measurement, divided by the baseline ROM measurement, and multiplying by 100.
Baseline and post-treatment (visit occurred between 113 - 127 days from baseline)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Daniel D Lozano, MD, Lehigh Valley Health Network

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Mai 2013

Primärer Abschluss (Tatsächlich)

1. Mai 2016

Studienabschluss (Tatsächlich)

1. Juli 2016

Studienanmeldedaten

Zuerst eingereicht

10. Mai 2013

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

20. Mai 2013

Zuerst gepostet (Schätzen)

21. Mai 2013

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. Oktober 2021

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. September 2021

Zuletzt verifiziert

1. September 2021

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • FI-B-003

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Restrictive Burn Scars

Klinische Studien zur Autologous fibroblasts

3
Abonnieren